Biopharma SHAKTI Scheme

1. At a Glance

• Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology & Innovation — a Union scheme to build a globally competitive domestic ecosystem for biologics and biosimilars [1][3].
• Outlay of ₹10,000 crore over five years, announced in Union Budget 2026-27 under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [1][2].
• Aspirants must know it as India's flagship push to move beyond generic/conventional pharma into advanced biologics, biosimilars, gene therapy, and bio-manufacturing, complementing PLI-Pharma and BioE3 policy [2][3].

2. Why in the News

• PIB clarification (17 March 2026) by Department of Pharmaceuticals reiterating the scheme's outlay and seven components; "contours of the scheme are under deliberation" [1].
• Originally proposed in Union Budget 2026-27 speech as part of the push to scale manufacturing in 7 strategic frontier sectors [3][4].
• Union Minister Dr. Jitendra Singh flagged it as catalysing India's role in the "next industrial revolution" and a global bio-manufacturing hub [2].

3. Background & Evolution

• Builds upon earlier biotech-pharma interventions: National Biopharma Mission (NBM, 2017) by DBT-BIRAC (World Bank co-funded, USD 250 mn) and PLI Scheme for Pharmaceuticals (2021) [3].
• Aligned with the BioE3 Policy (2024) of the Department of Biotechnology — Biotechnology for Economy, Environment & Employment [3].
• Announced in Union Budget 2026-27 by Finance Minister; PIB explainer issued Feb 2026; detailed component-wise PIB release on 17 Mar 2026 [1][3].

4. Core Static Facts

• Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals (DoP) [1].
• Outlay: ₹10,000 crore over 5 years [1][2].
• Target market share: capture ~5% of the global biopharmaceutical market [3].
• Seven Components [1][3]: 1. Biopharma Discovery Grant Fund & Discovery & Development Equity Fund. 2. Biopharma-focused NIPER Network + National Biopharma R&D Network (3 new NIPERs + upgradation of 7 existing NIPERs) [2]. 3. India Clinical Trial Sites Network — 1,000 accredited sites [1][3]. 4. Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive. 5. Biopharma Delivery Devices & Packaging Manufacturing Ecosystem. 6. Biosimilars & Emerging Biologics Manufacturing Initiative. 7. Regulatory Strengthening — dedicated Scientific Review Cadre in CDSCO, including specialists for gene therapy [2][3].

5. Multi-Dimensional Analysis

• Economic: Reduces import dependence on biologics (high-value imports), targets 5% of global biopharma market, expands bioeconomy beyond conventional generics [2][3].
• Scientific / Technological: Pivot to gene therapy, biosimilars, fermentation-based APIs; institutional R&D backbone via NIPER expansion and biopharma R&D network [2].
• Administrative / Regulatory: Modernises CDSCO with specialist reviewer cadre to deliver "global-best drug review standards and approval timeframes" [2][3].
• Strategic: Frames biopharma as a frontier strategic sector under Budget 2026-27's 7-sector manufacturing scale-up; positions India as a global biomanufacturing hub [2][4].
• Social: Aims to support affordable healthcare by domesticising biologics/biosimilars production [1].

6. Recent Developments (last 12-18 months)

• Feb 2026: Biopharma SHAKTI announced in Union Budget 2026-27 [3][4].
• Feb 2026: PIB Budget Series explainer "Transforming India into a Global Biopharma Hub" published [3].
• 17 Mar 2026: DoP PIB release confirms ₹10,000 cr outlay, lists 7 components, notes contours under deliberation [1].
• Coupled budgetary push: provision flagged for BioPharma SHAKTI alongside 3 dedicated Chemical Parks [4].

7. Prelims Hooks

• SHAKTI expands to Strategy for Healthcare Advancement through Knowledge, Technology & Innovation [3].
• Outlay = ₹10,000 crore / 5 years [1].
• Nodal department = Department of Pharmaceuticals (NOT DBT, NOT MoHFW) [1].
• Parent ministry = Ministry of Chemicals & Fertilizers [1].
• Announced in Union Budget 2026-27 [3].
• 1,000 accredited clinical trial sites proposed under India Clinical Trial Sites Network [1][3].
• 3 new NIPERs + 7 upgraded NIPERs under the NIPER Network component [2].
• Regulatory body to be strengthened = CDSCO (Central Drugs Standard Control Organisation) [2].
• Includes Fermentation-based Bulk Drugs & Building Blocks incentive [1].
• Focus areas = biologics, biosimilars, gene therapy, delivery devices & packaging [2][3].
• Predecessor mission = National Biopharma Mission (2017) under DBT-BIRAC [3].
• Target = capture ~5% of global biopharma market [3].

8. Mains Relevance

• GS-III — Indian Economy (manufacturing, growth); Science & Technology (indigenisation, biotech, IPR); Health.
• Syllabus headings: "Achievements of Indians in S&T; indigenisation of technology"; "Government Budgeting"; "Issues relating to development & management of social sector — Health".
• Possible question stems:
• "The Biopharma SHAKTI scheme marks a shift from a generics-led pharma economy to a biologics-led bioeconomy. Examine."
• "Discuss the role of regulatory reform (CDSCO) and clinical trial infrastructure in making India a global biopharma hub."
• "Critically assess fiscal incentives like Biopharma SHAKTI in reducing India's import dependence in high-value biologics."

9. Related Topics to Study Next

• BioE3 Policy 2024 — overarching biotech policy framework.
• National Biopharma Mission (NBM) & BIRAC — predecessor and implementing biotech body.
• PLI Scheme for Pharmaceuticals & Bulk Drugs — sister manufacturing-incentive scheme.
• CDSCO & New Drugs and Clinical Trials Rules 2019 — regulatory backbone.
• NIPERs — institutional pharma R&D ecosystem.
• India's Generic Pharma Industry / "Pharmacy of the World" — comparative base.
• Bulk Drug Parks Scheme — addresses upstream API dependency.
• Genome India Programme, gene therapy approvals — frontier biotech context.

10. Common Errors / Trap Areas

• Confusing nodal body: it is Department of Pharmaceuticals (Min. of Chemicals & Fertilizers), NOT Department of Biotechnology (DBT) or MoHFW.
• Confusing with National Biopharma Mission (2017, DBT-BIRAC, World Bank-aided) — that is a predecessor, not Biopharma SHAKTI.
• SHAKTI ≠ the SHAKTI coal-linkage policy of Ministry of Coal — same acronym, unrelated.
• Outlay is ₹10,000 cr / 5 yrs; a related PIB op-ed mentions ₹13,000 cr combining Biopharma SHAKTI + 3 Chemical Parks — do not conflate [1][4].
• Clinical trial sites figure is 1,000 accredited sites, not 100 or 10,000.